ARTICLE | Clinical News

Ofirmev regulatory update

November 8, 2010 8:00 AM UTC

FDA approved an NDA from Cadence for Ofirmev IV acetaminophen to treat pain and fever. As part of the approval, Cadence will conduct a post-marketing efficacy study of Ofirmev in infants and neonates. Cadence plans on launching Ofirmev in the U.S. in 1Q11. ...